ArticleBMC nephrology2025
Association of autosomal dominant polycystic kidney disease (ADPKD) with cardiovascular disease and mortality in patients with treated kidney failure.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutosomal dominant polycystic kidney disease (ADPKD) is a multisystem syndrome associated with significant morbidity and mortality, particularly kidney failure. This study sought to evaluate mortality and transplant outcomes in Australian and New Zealand patients with ADPKD commencing kidney replacement therapy (KRT).
methodsA retrospective review of all patients with kidney failure over 18 years of age commencing KRT between 1963 and 2020, stratified across eras, using Australia and New Zealand Transplant (ANZDATA) Registry data. People with ADPKD were compared to those with other causes of kidney failure (non-ADPKD). The primary outcome was mortality on dialysis. Secondary outcomes included post-kidney transplant patient survival and graft survival (both death-censored and with death as a competing risk). Outcomes were compared using multivariable Cox proportional hazards models.
resultsDuring the study period, 63,875 patients commenced KRT, including 2,466 (3.9%) with ADPKD. Compared to patients without ADPKD, those with ADPKD had generally fewer comorbidities at KRT initiation. ADPKD was independently associated with a lower risk of mortality on dialysis (adjusted hazard ratio [aHR], 0.71, 95% CI 0.67-0.75, p < 0.001). Causes of death were similar between the ADPKD and non-ADPKD cohorts including for cardiovascular disease (27.5% vs. 27.6%, respectively), infection (7.9% vs. 8.5%) and cancer (3.4% vs. 3.5%). Kidney transplant recipients had fewer comorbidities across both cohorts, with a similar incidence of coronary artery disease (ADPKD 7.2% vs. non-ADPKD 8.0%). Compared with non-ADPKD, ADPKD was associated with a similar mortality risk in kidney transplant recipients (aHR, 0.96, 95% CI 0.88-1.05) and slightly improved graft survival (aHR, 0.87; 95% CI 0.77-0.97, p < 0.05), although there was no difference in death-censored graft survival (aHR, 0.92, 95% CI 0.79-1.07).
conclusionsCompared to other causes of kidney failure, ADPKD is associated with better patient survival on dialysis, similar patient survival post-kidney transplantation and similar death-censored graft survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.